ProMIS Neurosciences to Report Third Quarter 2026 Financial Results and Business Update on November 12, 2026

ProMIS Neurosciences (Nasdaq: PMN) will report third-quarter 2026 financial results and provide corporate updates on November 12, 2026.

Rhea-AI Summary

ProMIS Neurosciences (Nasdaq: PMN) will report third-quarter 2026 financial results and provide corporate updates on November 12, 2026. The results cover the quarter ended September 30, 2026. A conference call and webcast will begin at 4:30 p.m. Eastern Time that day, with a webcast replay available afterward in the Investors section of the company website.

ProMIS has also published an investor Q&A, PMN310 Scientific and Clinical Update (November 2026), outlining the scientific rationale distinguishing PMN310 from other amyloid-targeting approaches.

Key Figures

Scheduled results date: November 12, 2026

Scheduled results date

November 12, 2026

Third-quarter financial results and business update

Key Terms

phase 1b, monoclonal antibody, igg1, amyloid-beta

4 terms

phase 1b medical

"lead asset in Phase 1b development"

"Phase 1b" is an early stage in testing a new medical treatment or vaccine, where it is given to a small group of people to evaluate its safety and determine the right dose. For investors, this phase signals progress in development, indicating the treatment is advancing through initial safety checks, which can influence expectations for future success and potential market impact.

monoclonal antibody medical

"is a humanized IgG1 monoclonal antibody"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

igg1 medical

"is a humanized IgG1 monoclonal antibody"

IgG1 is one of the major human antibody subtypes that patrol the blood and tissues; think of it as a common model of a tool the immune system uses to recognize and neutralize threats. In drug development, many therapeutic antibodies are built on an IgG1 backbone because its characteristics — how long it stays in the body, how strongly it engages immune cells, and its safety profile — affect a medicine’s effectiveness, side‑effect risks, dosing schedule and commercial potential, which are key factors for investors.

amyloid-beta medical

"toxic oligomers of amyloid-beta (AβOs)"

Amyloid-beta is a small protein fragment that can clump into sticky deposits in the brain, like crumbs piling up and getting in the way of normal cell work; these deposits are linked to memory loss and dementia. Investors care because diagnostic tests, drugs, or devices that detect, reduce, or remove these clumps can change regulatory outcomes, treatment standards and the commercial value of companies developing Alzheimer’s-related products.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company to host investor conference call and webcast at 4:30 p.m. ET.

Cambridge, Massachusetts, Nov. 03, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced it will report financial results for the third quarter ended September 30, 2026, and provide corporate updates on November 12, 2026.  The company will host a conference call and webcast on the same day at 4:30 p.m. ET.

Conference Call and Webcast Information:

Date:	November 12, 2026
Time:	4:30 p.m. Eastern Time
Dial-in:	1-877-407-9208 (U.S. Investors) 1-201-493-6784 (International)
Conference I.D.:	13762779
CallMeTM:	Click Here
Webcast:	Click Here

A replay of the webcast will be available in the Investors section of the ProMIS website following the completion of the call.

ProMIS has also published an investor Q&A outlining the scientific rationale that differentiates PMN310 from other amyloid-targeting approaches, available in the Investors section of the ProMIS website: PMN310 Scientific and Clinical Update (November 2026).

About ProMIS Neurosciences Inc.

ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company’s proprietary target discovery engine, EpiSelect™, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson’s disease (PD). ProMIS’ lead asset in Phase 1b development, PMN310, is a humanized IgG1 monoclonal antibody designed to selectively target only the toxic oligomers of amyloid-beta (AβOs), believed to be among the earliest and most damaging drivers of Alzheimer’s disease, while avoiding binding to amyloid plaques and vascular deposits. ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).

Investor Relations Contact
Carie Pierce
VP Investor Relations & External Affairs
IR@ProMISNeurosciences.com

Media Contact
Maggie Whitney
LifeSci Communications
mwhitney@lifescicomms.com

For further information:
Visit us at www.promisneurosciences.com